Phase 2b data from EASD 2026 show the amylin-incretin combination also cut HbA1c by up to 2.9% in adults with obesity or overweight and type 2 diabetes.
|Videos|March 23, 2018
Utilizing Pharmacists in a Team-Based Diabetes Care Model
In this clip, Traci Fritschle, PharmD, explains why pharmacists are uniquely positioned to be utilized in a team-based model for diabetes care.
Advertisement
In this clip, Traci Fritschle, PharmD, explains why pharmacists are uniquely positioned to be utilized in a team-based model for diabetes care. Pharmacists can impact patient care by incorporating face-to-face interactions to review patient reports, discuss trends seen in the report, and explain the impact of the patient's choices with medication adherence and lifestyle behavior.
Advertisement
Related to this article
Indirect comparison links orforglipron 17.2 mg to 1.5% more weight loss and 0.3% more A1C lowering than oral semaglutide 25 mg in adults with type 2 diabetes.
Phase 3 TRIUMPH-2 data presented at EASD show HbA1C reductions up to 1.6%, with GI effects, hypotension, and dysesthesia as key counseling points.
fMRI data show cagrilintide-semaglutide altered brain responses to high-calorie food cues; REIMAGINE analyses point to ectopic fat and bone effects.
A Novo Nordisk–funded claims analysis of adults with type 2 diabetes found an adjusted HR of 1.06 for MACE with switching, although the findings cannot show causation.
A new analysis finds a significant weight loss edge for tirzepatide under one estimand but not another; no head-to-head trial exists at these doses.
A behavioral walking program matched supervised aerobic training for improving asthma control in a randomized trial of physically inactive adults.
American Pharmacists Month kicked off on October 1, honoring more than 700,000 pharmacy professionals and 250 years of caring for America's communities.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Why Lp(a) Testing Lagged Behind LDL Cholesterol Screening
2
What the 2025-2030 Dietary Guidelines Mean for Heart Health
3
FDA Approves Pirtobrutinib for Previously Untreated CLL/SLL
4
EloraTZP Delivers Up to 23.3% Weight Loss in Adults With Obesity and T2D
5